Lantheus Medical Imaging Inc. has received a Special Protocol Assessment (SPA) approval for a Phase 3 clinical trial for the assessment of myocardial perfusion using PET imaging of an injection agent in patients with suspected coronary artery disease.
Lantheus Medical Imaging Inc. has received a Special Protocol Assessment (SPA) approval for a Phase 3 clinical trial for the assessment of myocardial perfusion using PET imaging of an injection agent in patients with suspected coronary artery disease.
The company plans to start the first of two planned trials of flurpiridaz F-18 in the second quarter of 2011. An SPA means the company’s proposed trial protocol is acceptable for approval.
“We believe that flurpiridaz F-18 can improve the diagnosis and evaluation of coronary artery disease, ultimately reducing the need for additional medical tests and procedures,” Lantheus president and CEO Don Kiepert said in a statement.
Data from a preliminary Phase 2 trial showed that PET imaging with flurpiridaz F-18 provided better image quality than technetium-99m sestamibi singe photon emission computer tomography (SPECT), which is the current standard for noninvasive detection of CAD, according to the company. A full data set from the Phase 2 clinical trial will be presented in May at the Nuclear Cardiology and Cardiac CT Conference.
The goal of the Phase 3 trial is to assess the sensitivity and specificity of flurpiridaz F-18 injection PET myocardial perfusion imaging in about 1,350 patients with known or suspected CAD at about 100 clinical sites.
AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses on CT
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.